Related references
Note: Only part of the references are listed.Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study
Julien Kirchgesner et al.
GUT (2020)
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
Matthew Bohm et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Bruce E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease
Sebastian Zeissig et al.
GUT (2019)
Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease
S. Singh et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases
Julien Kirchgesner et al.
GASTROENTEROLOGY (2018)
Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials
Brian G. Feagan et al.
JOURNAL OF CROHNS & COLITIS (2018)
Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis
S. Singh et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014
J. Kirchgesner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frederic Colombel et al.
GUT (2017)
Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database
Line Sahli et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2016)
Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases
M. S. Broder et al.
PITUITARY (2014)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Validity of computerized diagnoses, procedures, and drugs for inflammatory bowel disease in a northern California managed care organization
Liyan Liu et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Share Paper
